The world's first human trial of whether a drug can essentially make a person's cells younger sets up a reality check for one of the longevity field's most promising theories.
Why it matters: The early-stage clinical trial will signal whether "cellular reprogramming" can be performed safely in humans, a prerequisite for any future claim that a treatment can slow or even reverse biological aging.
The Federal Trade Commission and four states on Wednesday sued a trade group for gender-affirming care providers, claiming it made false and unsubstantiated claims about the benefits of transition-related services.
Why it matters: The complaint in a federal court in Texas opens another front in the Trump administration's efforts to limit the availability of puberty blockers, hormone therapies and other forms of care.
More reports ofworkplace violence in hospitals and clinics are reviving calls for a federal standard to protect nurses, social workers and others in medical settings.
Why it matters: Health care workers have been among the likeliest to experience threats or be assaulted on the job since the onset of the pandemic.
Nursing home staffing levels have mostly bounced back to pre-pandemic levels after cratering during the health emergency.
Why it matters: The nursing home industry pointed to staffing shortages and difficulty hiring new workers in its successful fight against the Biden administration's first-ever minimum staffing requirements.
